Baltimore Sues Biogen Over Generic Drug Entry Plan, High Prices

A class action filed by the city of Baltimore is alleging Biogen Inc. unlawfully orchestrated a scheme working with the nation’s largest pharmacy benefit managers to impair competition from generic versions of its brand-name drug Tecfidera.

Biogen “crafted a market-switch strategy” to stall generic competition for Tecfidera—a drug used to treat multiple sclerosis—when it developed a “next generation” version of its drug called Vumerity, the city of Baltimore wrote Sept. 20 in a complaint filed in the US District Court for the Northern District of Illinois.

“Vumerity was different from Tecfidera not in a medically important way, but in an ...